RE: the seller...6 Dec 2016 14:03
It's the risk aspect that flagged it up for me in the first place mate and Motley Fool's/ST's timely deramp suggesting only for the brace and high risk etc flew in the face of common sense to my thinking - they're going to phase three, clearly they wouldn't be doing that if they weren't highly encouraged by the results as they see them and, moreover, for a treatment that would stand entirely on its own globally as a treatment for stroke disabilities ...
It's a crowded market out there for lots of disease treatments but stroke victims (100s of thousands of people) isn't one of them and neither is the broader target of improving brain function for diseases like dementia which are wreaking havoc amongst an increasingly large susceptible aging population in the developed world ...